Debut Of Merck's Anacetrapib Debut Many Years Away, Despite Robust Phase III Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing will wait until after 2015, pending results of a soon-to-launch CV outcomes study of the CETP inhibitor in 30,000 patients.